GlassScriptPhysician profile
Sanjay A Vora
NPI 1467459180
$7,432.76
in general payments reported to CMS, 2019-2025
45 companies · $1,344 in 2025
The $1,344 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $654 · 2020: $423 · 2021: $960 · 2022: $1,221 · 2023: $1,349 · 2024: $1,483 · 2025: $1,344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,176.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $985.91 | 2019-2025 | Evenity, Repatha, Prolia |
| Astrazeneca Pharmaceuticals LP | $764.68 | 2019-2025 | Airsupra, Farxiga, Lokelma |
| Novo Nordisk INC | $594.64 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $539.65 | 2020-2025 | Trelegy Ellipta, Shingrix, Benlysta |
| Abbvie INC. | $498.10 | 2021-2024 | Qulipta, Ubrelvy |
| Novartis Pharmaceuticals Corporation | $359.51 | 2019-2025 | |
| Pfizer INC. | $314.70 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $302.22 | 2019-2022 | |
| Lilly USA, LLC | $300.45 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $268.93 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $250.56 | 2020-2025 | Jardiance |
| Travere Therapeutics, INC. | $246.43 | 2023-2025 | |
| Fresenius USA Marketing, INC. | $182.34 | 2019-2025 | Velphoro, Velphoro |
| Aurinia Pharma U.S., INC. | $162.04 | 2021-2025 | Lupkynis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $161.63 | 2022-2025 | Xifaxan, Relistor |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $151.93 | 2019-2025 | Jynarque, Voyxact |
| Takeda Pharmaceuticals U.S.A., INC. | $146.35 | 2020-2023 | Gattex |
| E.R. Squibb & Sons, L.L.C. | $140.98 | 2019-2024 | Eliquis |
| Calliditas Therapeutics US INC. | $120.97 | 2022-2025 | Tarpeyo |
| Abbott Laboratories | $92.01 | 2019-2022 | |
| Astellas Pharma US INC | $83.49 | 2023-2024 | Veozah, Myrbetriq |
| Xeris Pharmaceuticals, INC. | $65.72 | 2023-2025 | Keveyis |
| Mallinckrodt Hospital Products INC. | $60.58 | 2020-2022 | |
| Exact Sciences Corporation | $59.24 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Genzyme Corporation | $58.38 | 2019 | |
| Ardelyx, INC. | $57.00 | 2024 | Ibsrela |
| Inspire Medical Systems, INC. | $55.27 | 2024 | Inspire |
| Horizon Therapeutics Plc | $50.24 | 2022-2023 | Krystexxa |
| Mallinckrodt Enterprises LLC | $33.94 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $32.84 | 2022 | |
| Merck Sharp & Dohme LLC | $31.10 | 2020-2023 | Verquvo |
| Bardy Diagnostics, INC. | $30.90 | 2022 | |
| Akebia Therapeutics INC | $29.14 | 2019 | |
| Ani Pharmaceuticals, INC. | $26.00 | 2025 | Purified Cortrophin Gel |
| Sanofi-Aventis U.S. LLC | $25.88 | 2024 | |
| Phadia US INC. | $19.76 | 2023 | Immunocap |
| Alnylam Pharmaceuticals INC. | $19.30 | 2025 | Onpattro |
| Apellis Pharmaceuticals, INC. | $16.54 | 2025 | Empaveli |
| Actelion Pharmaceuticals US, INC. | $16.53 | 2024 | Opsumit, Uptravi |
| Pharmacosmos Therapeutics INC. | $15.16 | 2024 | Monoferric |
| Stryker Corporation | $14.13 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Amarin Pharma, INC. | $12.80 | 2020 | |
| Allergan, INC. | $12.20 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $11.58 | 2021 | |
| Bard Peripheral Vascular, INC. | $11.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Vora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.